Antihyperlipidemic, anti-inflammatory, analgesic, and antipyretic activities of "dimethyl dimethoxy biphenyl dicarboxylate" in male Wistar rats.

Autor: Abdallah HMI; Department of Pharmacology, Division of Medical Sciences, National Research Centre, Dokki, Giza, Egypt., Asaad GF; Department of Pharmacology, Division of Medical Sciences, National Research Centre, Dokki, Giza, Egypt., Arbid MS; Department of Pharmacology, Division of Medical Sciences, National Research Centre, Dokki, Giza, Egypt., Nomier YA; Department of Pharmacology and Toxicology, Pharmacy College, Jazan University, Jazan, Saudi Arabia.
Jazyk: angličtina
Zdroj: Journal of advanced pharmaceutical technology & research [J Adv Pharm Technol Res] 2022 Apr-Jun; Vol. 13 (2), pp. 83-88. Date of Electronic Publication: 2022 Apr 07.
DOI: 10.4103/japtr.japtr_292_21
Abstrakt: Dimethyl dimethoxy biphenyl (DDB) dicarboxylate has been applied as a therapeutic modality for curing liver diseases, particularly hepatitis virus. The objective of this study was to assess the protective potential against Triton X-100 induced abnormal fat metabolism in addition to anti-inflammatory, analgesic, and antipyretic effects of DDB. The anti-inflammatory, antinociceptive, and antipyretic of DDB were investigated through induction of paw edema, pain, and fever in experimental rats. DDB decreased cholesterol and triglyceride contents. DDB resulted in inhibition of inflammation, nociception, and fever in the experimental models. DDB improved lipid profile, as evidence of hypolipidemic potential. It also showed anti-inflammatory, analgesic, and antipyretic properties.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2022 Journal of Advanced Pharmaceutical Technology & Research.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje